Department of Psychiatry
Penn Behavioral Health

Center for Studies of Addiction

subpage feature

Addiction Treatment and Medication Development Division

Clinical Trials


The Addiction Treatment and Medication Development Division is conducting a number of clinical trials that are on-going or soon to begin.

If you are interested in getting more information about any of these studies, please call 215-243-9959.




ALCOHOL TREATMENT STUDIES

Study Name: Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT ® (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder (Horizant)
Diagnosis: Alcohol Use Disorder
Age:  21 and up
Study Involves: Alternating phone and in-clinic visits for medical management (MM), laboratory tests, and physical exams, to assess drug compliance, to complete additional questionnaires, and to provide counseling (via “Take Control” videos) over 29 weeks. 
Duration: Up to 7 months including follow up
Study Status: Active – recruiting participants


 




COCAINE TREATMENT STUDIES

Study Name: Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence: A Phase III, Randomized, Double-Blind Trial of Adderall-XR and Topiramate (TACT)
Diagnosis or Problem: Cocaine Dependence
Age: 18-60
Study involves: Three visits weekly that include medical management (MM) and a supportive behavioral treatment to enhance adherence to the study drug
Duration: 15 weeks plus follow up visit
Study Status: Active – recruiting participants

 

Study Name: A Phase II Randomized, Double-blind, Placebo-Controlled,  Trial of Varenicline (Chantix™) for the Treatment of Cocaine Dependence (Chantix Cocaine 2)
Diagnosis or Problem: Cocaine Dependence
Age: 18-65
Study involves: Three visits weekly for the purposes of medical management (MM), cognitive behavioral therapy (CBT), to complete questionnaires and assess drug compliance
Duration: 12 weeks
Study Status: Active – recruiting participants

 


OPIOID TREATMENT STUDIES

Study Name: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine (RBP-6000 [100 mg and 300 mg]) Over 24 Weeks in Treatment-Seeking Subjects with Opioid Use Disorder (Reckitt)
Diagnosis or Problem: Opioid Use Disorder
Age:  18-65 years of age
Study Involves: Up to 33 weeks, including Screening (up to 2 weeks), Induction (up to 2 weeks), Maintenance/active or placebo study drug dosing(25 weeks), and Follow-up (4 weeks).
Duration: 33 weeks
Study Status: Active - recruiting participants

 

 

 

 

 

 

 

 





 

 


 



 

< back to Addiction Treatment main page